CKD-349 / Chong Kun Dang - LARVOL DELTA

Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Renal Disease

Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=71 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed

Trial completion • Cardiovascular • Heart Failure

Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2021 ➔ Mar 2022

Clinical • Enrollment open • Trial completion date • Cardiovascular • Heart Failure

Study to Evaluate the Safety and Pharmacokinetics of CKD-349 (clinicaltrials.gov) - P1; N=70; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Cardiovascular • Heart Failure

Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Chronic Kidney Disease • Renal Disease